Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

NCT01623596 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

881

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Fingolimod
DRUG: Disease Modifying therapy

Sponsor

Novartis Pharmaceuticals